GoodRx price target raised to $7.50 from $5.50 at Truist

Truist raised the firm’s price target on GoodRx to $7.50 from $5.50 and keeps a Hold rating on the shares. The firm cites the company’s positive Q4 pre-announcement as the management expects the volume benefit as result of its direct contracting efforts to be recurring, the volume benefit as result of seasonal elements to likely go away, and the rates to benefit as a result of Q4-specific favorability in certain client contracts in Q4 to be non-recurring, the analyst tells investors in a research note.